ReviewMaterials today. Bio2026
Rational design of immunological programs for functional regenerative niches.
Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The immune system is a master conductor of tissue repair, yet its therapeutic potential remains underexploited. Moving beyond descriptive biology, we propose 'immunoprogramming' as an active design paradigm that synergistically integrates stem cells and biomaterials to steer host immunity toward pro-regenerative outcomes. Here, we decode the source-specific immunomodulatory signatures of stem cells-from bone marrow and adipose tissue to dental and iPSC-derived populations-and establish how the biochemical and biophysical language of engineered biomaterials can directly command innate and adaptive immune cell fate. Crucially, we emphasize that within integrated cell-scaffold constructs, a bidirectional crosstalk emerges: the biomaterial primes the stem cell, which in turn execute enhanced context-specific immunomodulation. To translate this synergy into a design discipline, we introduce the Synergistic Immuno-Instructional System (SIIS) framework, which modularizes Cell-Source-Specific Immuno-Modules (CSIMs), Biomaterial-Based Immuno-Code (BIC), and Tissue-Specific Immuno-Niche (TSIN). Finally, we discuss translational challenges and advocate for next generation 'immuno-informed' therapeutics that evolve from passive replacement to active immune niche engineering, charting a course for intelligent regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.